Journal of Translational Medicine, Год журнала: 2024, Номер 22(1)

Опубликована: Авг. 5, 2024

Asthma poses a major public health burden. While existing asthma drugs manage symptoms for many, some patients remain resistant. The lack of cure, especially severe asthma, compels exploration novel therapies. Cancer immunotherapy successes with CAR-T cells suggest its potential treatment. Researchers are exploring various approaches allergic diseases including membrane-bound IgE, IL-5, PD-L2, and CTLA-4 Dectin-1 fungal asthma. NK offer several advantages over T CAR-based immunotherapy. They key benefits: (1) HLA compatibility, meaning they can be used in wider range without the need matching tissue types. (2) Minimal side effects (CRS GVHD) due to their limited persistence cytokine profile. (3) Scalability "off-the-shelf" production from sources. Several strategies have been introduced that highlight superiority challenges CAR-NK cell therapy treatment IL-10, IFN-γ, ADCC, perforin-granzyme, FASL, KIR, NCRs (NKP46), DAP, DNAM-1, TGF-β, TNF-α, CCL, NKG2A, TF, EGFR. Furthermore, we advocate incorporating AI CAR design optimization CRISPR-Cas9 gene editing technology precise manipulation generate highly effective constructs. This review will delve into evolution designs, explore pre-clinical clinical studies therapies analyze optimize function, conduct comparative analysis respective challenges, finally present established designs promising

Язык: Английский